Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte presented Phase 1/2 data for VGA039 (latarcibart) showing an 81% median reduction in annualized bleeding rates across all von Willebrand disease types. The subcutaneous therapy was safe and well tolerated over multiple doses, with patients switching from IV prophylaxis experiencing bleed reductions of 75-100%.
Key figures
- Drug Name
- VGA039 (Latarcibart)
- Phase Of Trial
- Phase 1/2
- Abr reduction
- 81% median reduction
- Patient count
- 16
- Prior prophylaxis reduction
- 75-100%
- Breakthrough bleed reduction
- ~86%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.